MP
OVID icon

Mangrove Partners’s Ovid Therapeutics OVID Stock Holding History

Mangrove Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,294
Closed -$60.6K – 543
2026
Q1 		$60.6K Buy
+27,294
New +$48.8K ﹤0.01% 410

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Mangrove Partners's OVID Position: Q2 2026 in Review

Mangrove Partners sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 27,294 shares — an estimated $60.6K sold.

Mangrove Partners first reported a position in OVID in Q1 2026 and held it in 1 quarter. The position peaked at $60.6K in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Mangrove Partners reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mangrove Partners sold 27,294 Ovid Therapeutics shares in Q2 2026, an estimated $60.6K.
  • Mangrove Partners first reported a position in Ovid Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mangrove Partners's Ovid Therapeutics position peaked at $60.6K in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.